Vivo Bio Tech Peer Comparison

BSE: 511509

₹18.11

₹-0.69 (-3.67%)

As on 28-Aug-2026IST

Market cap

₹40 Cr

Revenue (TTM)

₹55 Cr

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Vivo Bio Tech	Dishman Carbogen	Genomic Biotech	Indegene	Lyka Labs	Marksans Pharma	Sai Life Sciences	Sanofi Consumer Healthcare India	Take Solutions
Market cap (₹ Cr)	40	2,746	9	13,940	269	14,932	31,434	9,704	241
Revenue (₹ Cr)	55	2,901	0	3,813	138	3,172	2,250	950	85
Net Profit (₹ Cr)	-2.86	16.16	0.02	400.90	-9.39	521.27	361.74	266.00	12.82
Net Margin (%)	-5.15	0.55	9.72	10.30	-6.66	15.92	15.77	27.44	6.38
RoE (%)	-16.06	0.29	0.53	13.87	-9.20	18.10	15.47	72.69	20.84
Price to Earnings	--	169.93	419.92	34.77	--	28.90	86.90	36.48	18.78
Price-To-Book	0.44	0.41	2.24	4.34	2.85	4.70	12.31	27.89	7.51

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Operating Revenue	55.10	2,901.49	137.73	84.56	0.22
Total Income	55.46	2,950.84	141.01	92.53	0.22
Total Expenditure	34.09	2,416.46	140.53	86.29	0.18
EBITDA	21.01	485.03	-2.80	-1.73	0.04
Depreciation	11.51	348.02	8.36	0.01	0.00
EBIT	9.50	137.01	-11.16	-1.74	0.03
Interest	5.58	168.51	3.32	0.18	0.00
Other Income	0.36	49.35	3.29	7.97	0.00
Exceptional Items	-0.61	-2.84	0.00	0.00	0.00
Profit before Tax	3.67	15.01	-11.19	6.06	0.03
Provision for Tax	6.53	-1.15	-1.80	0.16	0.01
Profit after Tax	-2.86	16.16	-9.39	5.90	0.02

Liabilities (₹ Cr)

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Shareholder's Funds	93.16	6,676.90	92.39	31.00	3.93
Minority Interest	0.00	0.00	0.49	0.00	0.00
Non-Current Liabilities	55.04	2,929.36	29.81	0.00	0.00
Current Liabilities	30.23	2,317.05	53.90	5.24	0.32
Total Liabilities	143.23	9,986.90	176.20	36.48	4.36

Assets (₹ Cr)

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Non-Current Assets	149.74	8,580.12	88.99	0.00	1.55
Current Assets	28.42	2,842.10	63.28	23.77	2.70
Total Assets	143.23	9,986.90	176.20	36.48	4.36
Total Debt*	54.03	2,083.91	38.00	0.00	0.00
Net Current Assets	-1.82	525.05	9.38	18.53	2.38
Contingent Liabilities	--	423.42	26.88	74.49	--

Cashflow (₹ Cr)

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Cash From Operating Activities	11.83	375.23	1.90	-16.37	0.03
Cash Flow from Investing Activities	-15.84	-192.21	-11.80	22.21	0.01
Cash from Financing Activities	3.90	-102.09	5.29	-3.24	--
Net Cash Inflow / Outflow	-0.11	80.93	-4.60	2.60	0.04

Ratios

Profitability Ratios

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
ROCE (%)	12.63	2.31	10.01	13.63	11.87
ROE (%)	-16.06	0.29	-9.20	20.84	0.53
ROA (%)	-1.78	0.15	-5.35	16.23	0.49
EBIT Margin (%)	17.24	4.72	-8.10	-2.05	14.35
Net Margin (%)	-5.15	0.55	-6.66	6.38	9.72
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Revenue Growth (%)	12.34	0.20	-2.60	-100.00	-72.27
EBIT Growth (%)	-22.16	-50.39	-203.38	67.89	-90.43
Net Profit Growth (%)	-133.81	-84.49	-222.82	81.10	-91.46
EPS Growth (%)	-230.45	-85.24	-218.89	81.10	-91.46
Book Value Growth (%)	30.20	3.63	76.48	331.34	10.05

Valuation Ratios

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Price / Earnings	-2.65	147.54	-29.77	40.81	419.92
Price / Book Value	0.44	0.41	2.85	7.51	2.24
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	4.44	8.86	-112.98	-137.15	250.66
Market Cap (₹ Cr)	58.31	3,411.88	360.30	--	17.90

Solvency Ratios

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Debt to Equity	0.50	0.23	0.25	0.00	0.00
Short term debt to equity ratio	0.15	0.11	0.14	--	--
Current Ratio	0.94	1.23	1.17	4.54	8.40
Quick Ratio	0.67	0.79	0.92	4.54	7.52
Interest Coverage	1.66	1.09	-2.37	35.64	2,845.31

Operating Efficiency Ratios

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Debtors to sales (%)	21.32	23.19	25.44	0.26	1,073.15
Asset Turnover	0.34	0.26	0.79	2.33	0.05
Receivable days	90.11	77.38	92.33	--	1,026.01
Inventory Days	64.77	120.02	29.04	--	122.93
Payable days	64.32	172.74	88.82	--	554.30
Cash Conversion Cycle	90.56	24.66	32.55	--	594.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.